Andrew Potterton
About Andrew Potterton
Andrew Potterton serves as the Head of Platform at Celeris Therapeutics, where he focuses on developing impactful products in structural biology and cheminformatics. He holds a PhD from UCL and has extensive experience in cheminformatics, having previously worked at BenevolentAI and Evotec.
Work at Celeris Therapeutics
Andrew Potterton serves as the Head of Platform at Celeris Therapeutics, a position he has held since 2023. In this role, he focuses on developing innovative solutions in the field of drug discovery. His work emphasizes the integration of structural biology and cheminformatics to create impactful products that advance therapeutic development.
Education and Expertise
Andrew Potterton completed his Doctor of Philosophy (PhD) from University College London (UCL) as part of the BBSRC Lido iCASE Studentship program, studying from 2016 to 2020. He also holds a Bachelor of Science (BSc) in Biochemistry from UCL, which he obtained from 2013 to 2016. His educational background provides a strong foundation in biochemistry and cheminformatics.
Background in Cheminformatics
Prior to his current role, Andrew Potterton worked at BenevolentAI in various capacities. He served as a Senior Cheminformatics Data Scientist from 2022 to 2023 and as an Advanced Cheminformatics Data Scientist from 2020 to 2022. His experience in cheminformatics has equipped him with the skills necessary to contribute to drug discovery processes effectively.
Research Experience at UCL and Evotec
Andrew Potterton gained significant research experience during his time at UCL, where he worked as a Researcher and PhD Candidate from 2016 to 2020. Additionally, he completed a PhD Placement at Evotec, further enhancing his research capabilities. This combination of academic and industry experience has shaped his approach to drug discovery.
Collaborative Approach to Goals
Andrew Potterton enjoys collaborating with individuals from diverse backgrounds to achieve shared goals. This collaborative mindset is evident in his work, where he seeks to integrate various perspectives and expertise to enhance the drug discovery process.